Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Barinthus Biotherapeutics PLC maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -62.26%, provide a clear picture of how effectively BRNS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BRNS competes directly with industry leaders such as SKYE and DARE. With a market capitalization of $24.98M, it holds a leading position in the sector. When comparing efficiency, BRNS's gross margin of N/A stands against SKYE's N/A and DARE's 100.00%. Such benchmarking helps identify whether Barinthus Biotherapeutics PLC is trading at a premium or discount relative to its financial performance.
